Abstract 1164P
Background
The standard approach for managing locally advanced rectal cancer includes preoperative neoadjuvant chemoradiotherapy followed by curative surgery, a regimen acknowledged for substantially enhancing local control rates. Nevertheless, the benefits of perioperative radiotherapy in treating rectal neuroendocrine carcinoma merit further investigation. This study explores the impact of preoperative neoadjuvant radiotherapy on the feasibility of sphincter-preserving surgery and on the overall survival rates in patients with locally advanced rectal neuroendocrine carcinoma.
Methods
Data from patients diagnosed with locally advanced (T3/T4 or N+) neuroendocrine carcinoma who underwent curative surgery from 2004 to 2019 were collected using the SEER database. We assessed clinical characteristics, treatment information, and overall survival rates. Statistical comparisons of categorical variables were performed using the Chi-square test or Fisher's exact test. Survival outcomes were analyzed using the Kaplan-Meier method.
Results
Of the 44 patients identified, 14 underwent preoperative neoadjuvant radiotherapy. Patients with a T-stage above T3 (42.9% vs. 12.5%, P = 0.049) and those without lymph node metastasis (87.5% vs. 19.4%, P < 0.001) were more likely to receive perioperative radiotherapy. The probability of performing sphincter-preserving surgery was notably lower in patients treated with neoadjuvant radiotherapy (57.1% vs. 93.3%, P = 0.008). Additionally, survival analysis indicated no significant relationship between neoadjuvant radiotherapy and overall survival (HR 1.298,95% CI:0.519-3. 244, P =0. 577).
Conclusions
Neoadjuvant radiotherapy prior to surgery did not improve the likelihood of performing sphincter-preserving procedures in patients with locally advanced rectal neuroendocrine carcinoma, nor did it significantly impact overall survival. Further research involving larger sample sizes is required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work, the author(s) used ChatGPT for editorial assistance in order to optimize content expression. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
W. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
951P - CA19-9-related macrophage polarization has prognostic value in patients with HCC after immune checkpoint inhibitor treatment
Presenter: Meiyan Zhu
Session: Poster session 17
952P - Comprehensive analysis of cytokines and PDL1 before and after administration of atezolizumab and bevasizumab in patients with HCC
Presenter: Kyoji Ito
Session: Poster session 17
953P - Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations
Presenter: Yanjiang Yin
Session: Poster session 17
954P - Evaluation of antigen-specific CD8 T cell responses to predict efficacy of atezolizumab and bevacizumab treatment in hepatocellular carcinoma
Presenter: Angélique Vienot
Session: Poster session 17
957P - Modelling immune-mediated cytotoxicity for HCC with patient-derived organoid co-culture platform
Presenter: Tsz Tung Kwong
Session: Poster session 17
958P - Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection
Presenter: Xinrong Yang
Session: Poster session 17
959P - Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
Presenter: Bin-Yan Zhong
Session: Poster session 17
960P - Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening
Presenter: Hee-Jung Wang
Session: Poster session 17